Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies
Vox Sanguinis · 2023
DOI: 10.1111/vox.13413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2023. Verfasst von Christian Gabriel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Tissue Donors, Dry Eye Syndromes. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives Serum eye drops (SEDs) are used to treat ocular surface disease (OSD) and to promote ocular surface renewal. However, their use and production are not standardized, and several new forms of human eye drops have been developed. Materials and Methods The International Society for Blood Transfusion Working Party (ISBT WP) for Cellular Therapies held a workshop to review the current types of eye drops of human origin (EDHO) status and provide guidance.
Results
The ISBT WP for Cellular Therapies introduced the new terminology ‘EDHO’ to emphasize that these products are analogous to ‘medical products of human origin’. This concept encompasses their source (serum, platelet lysate, and cord blood) and the increasingly diverse spectrum of clinical usage in ophthalmology and the need for traceability. The workshop identified the wide variability in EDHO manufacturing, lack of harmonized quality and production standards, distribution issues, reimbursement schemes and regulations. EDHO use and efficacy is established for the treatment of OSD, especially for those refractory to conventional treatments.
Conclusion
Production and distribution of single‐donor donations are cumbersome and complex. The workshop participants agreed that allogeneic EDHO have advantages over autologous EDHO although more data on clinical efficacy and safety are needed. Allogeneic EDHOs enable more efficient production and, when pooled, can provide enhanced standardization for clinical consistency, provided optimal margin of virus safety is ensured. Newer products, including platelet‐lysate‐ and cord‐blood‐derived EDHO, show promise and benefits over SED, but their safety and efficacy are yet to be fully established. This workshop highlighted the need for harmonization of EDHO standards and guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, Graz, Austria.
- Ludwig Boltzmann Institute for Clinical and Experimental Traumatology, Vienna, Austria.
- Research and Development, The Australian Red Cross Lifeblood, Sydney, Australia.
- Sydney Medical School, The University of Sydney, Sydney, Australia.
- Institute of Transfusion Medicine, University Hospital and Medical Faculty, University of Leipzig, Leipzig, Germany.
- Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.
ORCID-Profile: Christian Gabriel, Denese C Marks, Reinhard Henschler, Katharina Schallmoser, Thierry Burnouf, Mickey B C Koh
Zitieren
APA
Gabriel, C., Marks, D. C., Henschler, R., Schallmoser, K., Burnouf, T., & Koh, M. B. C. (2023). Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies. Vox Sanguinis. https://doi.org/10.1111/vox.13413
Vancouver
Gabriel C, Marks DC, Henschler R, Schallmoser K, Burnouf T, Koh MBC. Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies. Vox Sanguinis. 2023. doi:10.1111/vox.13413
BibTeX
@article{Gabriel2023,
author = {Gabriel, Christian and Marks, Denese C and Henschler, Reinhard and Schallmoser, Katharina and Burnouf, Thierry and Koh, Mickey B C},
title = {Eye drops of human origin—Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies},
journal = {Vox Sanguinis},
year = {2023},
doi = {10.1111/vox.13413}
}
EUVIMED